Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes

被引：0
|
作者：
Venugopal, Sangeetha [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
MDS; ASTX727; cedazuridine/decitabine; CC-486; oral AZA; SCORING SYSTEM; OPEN-LABEL; DECITABINE; AZACITIDINE; PHARMACOKINETICS; MULTICENTER; EFFICACY; CMML; MDS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EXABS-150-
引用
收藏
页码：S73 / S76
页数：4
相关论文
共 50 条
  • [1] Hypomethylating agents for the treatment of myelodysplastic syndromes
    Itzykson, Raphael
    Fenaux, Pierre
    [J]. BULLETIN DU CANCER, 2011, 98 (08) : 927 - 934
  • [2] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    [J]. CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
  • [3] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [4] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
    Finelli, Carlo
    Follo, Matilde Y.
    Stanzani, Marta
    Parisi, Sarah
    Clissa, Cristina
    Mongiorgi, Sara
    Barraco, Marilena
    Cocco, Lucio
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
  • [5] Optimizing hypomethylating agents in myelodysplastic syndromes
    Itzykson, Raphael
    Fenaux, Pierre
    [J]. CURRENT OPINION IN HEMATOLOGY, 2012, 19 (02) : 65 - 70
  • [6] Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes
    Wang, Rong
    Gross, Cary P.
    Maggiore, Ronald J.
    Halene, Stephanie
    Soulos, Pamela R.
    Raza, Azra
    Galili, Naomi
    Ma, Xiaomei
    [J]. LEUKEMIA RESEARCH, 2011, 35 (07) : 904 - 908
  • [7] The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes
    Kipp, David
    H Wei, Andrew
    [J]. FUTURE ONCOLOGY, 2021, 17 (20) : 2563 - 2571
  • [8] Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
    Festuccia, Moreno
    Baker, Kelsey
    Gooley, Theodore A.
    Sandmaier, Brenda M.
    Deeg, H. Joachim
    Scott, Bart L.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1509 - 1514
  • [9] Hematologic Outcomes of Myelodysplastic Syndromes Treatment With Hypomethylating Agents in Community Practice
    Bordoni, Rodolfo E.
    Feinberg, Bruce A.
    Gilmore, James W.
    Haislip, Sally
    Jackson, James H.
    Farrelly, Eileen
    Kim, Edward
    Buchner, Deborah
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (04): : 350 - 354
  • [10] Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment
    Zeidan, Amer M.
    Jayade, Sayeli
    Schmier, Jordana
    Botteman, Marc
    Hassan, Audrey
    Ruiters, Desiree
    Hill, Kala
    Joshi, Namita
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E185 - E198
12345